You have free access to this content

Cancer

Cover image for Vol. 118 Issue 1

1 January 2012

Volume 118, Issue 1

Pages 1–287

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Commentaries
    5. Original Articles
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Commentaries
    5. Original Articles
    1. You have free access to this content
      The rapid uptake of robotic prostatectomy and its collateral effects (pages 4–7)

      William T. Lowrance and Dipen J. Parekh

      Article first published online: 29 JUN 2011 | DOI: 10.1002/cncr.26275

      The shift in radical prostatectomy practice patterns toward robotic procedures has had substantial collateral effects, impacting the delivery, access, and cost of prostate cancer care in the United States. In this issue of Cancer, Stitzenberg and colleagues examine how the uptake of robotic surgery has influenced centralization of prostate cancer surgery and effected travel distances for patients seeking prostate cancer surgery. Undoubtedly, robotic surgery has changed the face of prostate cancer care in this country, but still more research is needed to further understand how delivery, access, and cost of health care are impacted by technological innovation.

    2. You have free access to this content
      Preoperative chemotherapy for bladder cancer : A standard waits to be optimally deployed (pages 8–11)

      Guru Sonpavde and Shahrokh F. Shariat

      Article first published online: 5 JUL 2011 | DOI: 10.1002/cncr.26239

      A retrospective study of neoadjuvant gemcitabine plus cisplatin in the current issue of Cancer highlights the activity of this regimen and its low frequency of employment. Directions for the further development of neoadjuvant therapy for bladder cancer are discussed.

    3. You have free access to this content
      What is the best way to treat high-risk prostate cancer? (pages 12–14)

      Eric A. Klein

      Article first published online: 30 JUN 2011 | DOI: 10.1002/cncr.26281

      The best treatment for high-risk, localized prostate cancer is unknown because of a lack of randomized trials comparing surgical versus radiation-based approaches. The relative merits and limitations of both approaches are debatable, and new combined modality treatments are needed.

  3. Commentaries

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Commentaries
    5. Original Articles
    1. You have free access to this content
      Does “in situ lymphoma” occur as a distinct step in the development of nodular lymphocyte-predominant Hodgkin lymphoma? (pages 15–16)

      Antonino Carbone

      Article first published online: 5 JUL 2011 | DOI: 10.1002/cncr.26228

      In situ lymphoma has now been recognized among early lesions in the development of overt lymphomas. Nodular lymphocyte-predominant Hodgkin lymphoma with a micronodular pattern in which small germinal centers (GCs) or broken-up GCs are present within nodules may be regarded as an early lesion limited to GCs and an in situ step potentially leading to overt lymphomas.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Commentaries
    5. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients (pages 17–26)

      Filippo Montemurro, Valentina Rossi, Maria Cossu Rocca, Rossella Martinello, Elena Verri, Stefania Redana, Laura Adamoli, Giorgio Valabrega, Anna Sapino, Massimo Aglietta, Giuseppe Viale, Aron Goldhirsch and Franco Nolè

      Article first published online: 19 MAY 2011 | DOI: 10.1002/cncr.26162

      The authors evaluated the predictive value of quantitative hormone receptor expression in patients with HER2-positive advanced breast cancer receiving trastuzumab and chemotherapy. Whereas high hormone receptor expression predicted reduced response rate, hormone receptor positivity was associated with a large progression-free survival benefit when endocrine therapy was added to trastuzumab after chemotherapy.

    2. You have free access to this content
      Physician over-recommendation of mammography for terminally ill women (pages 27–37)

      Corinne R. Leach, Carrie N. Klabunde, Catherine M. Alfano, Judith Lee Smith and Julia H. Rowland

      Article first published online: 16 JUN 2011 | DOI: 10.1002/cncr.26233

      Data from a nationally representative survey of primary care physicians from 2006 and 2007 were used to examine breast cancer screening recommendations for hypothetical patients ages 50 years, 65 years, and 80 years who were healthy, had a moderate comorbidity, or had a terminal comorbidity. The results suggest that over-recommendation of screening mammography is likely for terminally ill women and varies by physician and practice characteristics, including specialty.

    3. You have free access to this content
      Axillary lymph node failure in patients treated with accelerated partial breast irradiation (pages 38–43)

      Nayana Dekhne, Chirag Shah, J. Ben Wilkinson, Christina Mitchell, Peter Chen, Jeffrey Margolis and Frank Vicini

      Article first published online: 28 JUN 2011 | DOI: 10.1002/cncr.26305

      In selected patients with early stage breast cancer who received accelerated partial breast irradiation therapy, the risk of axillary failure was 0.2% at 5 years, and the regional failure rate was 0.4%. The rates of regional and axillary failure were comparable to the rates observed with traditional whole-breast irradiation.

    4. Genitourinary Disease
      You have free access to this content
      Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer : A multidisciplinary approach (pages 44–53)

      Ajjai S. Alva, Christopher T. Tallman, Chang He, Maha H. Hussain, Khaled Hafez, James E. Montie, David C. Smith, Alon Z. Weizer, David Wood and Cheryl T. Lee

      Article first published online: 19 MAY 2011 | DOI: 10.1002/cncr.26240

      The authors analyzed the timing between the termination of neoadjuvant chemotherapy and cystectomy and assessed its impact on the survival of patients with muscle-invasive bladder cancer. By using a multidisciplinary approach, the authors determined that the median time to cystectomy was 6.9 weeks. The results indicated that undergoing cystectomy within 10 weeks after the completion of neoadjuvant chemotherapy did not compromise cancer-specific or overall survival.

    5. You have free access to this content
      Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care (pages 54–62)

      Karyn B. Stitzenberg, Yu-Ning Wong, Matthew E. Nielsen, Brian L. Egleston and Robert G. Uzzo

      Article first published online: 29 JUN 2011 | DOI: 10.1002/cncr.26274

      Over the past decade, there has been widespread adoption of robotic-assisted prostatectomy and increasing centralization of prostate cancer surgery at high-volume centers. These changes have had a major impact on patterns of care and geographic access to care for patients with prostate cancer.

    6. You have free access to this content
      Dasatinib combined with docetaxel for castration-resistant prostate cancer : Results from a phase 1-2 study (pages 63–71)

      John C. Araujo, Paul Mathew, Andrew J. Armstrong, Edward L. Braud, Edwin Posadas, Mathew Lonberg, Gary E. Gallick, Géralyn C. Trudel, Prashni Paliwal, Shruti Agrawal and Christopher J. Logothetis

      Article first published online: 4 MAR 2011 | DOI: 10.1002/cncr.26204

      In a study of 46 men with castration-resistant prostate cancer, treatment with dasatinib plus docetaxel was well tolerated, and encouraging rates of tumor and bone responses were observed.

    7. You have free access to this content
      Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder (pages 72–81)

      Emil Scosyrev, Edward M. Messing, Edwin van Wijngaarden, Derick R. Peterson, Deepak Sahasrabudhe, Dragan Golijanin and Susan G. Fisher

      Article first published online: 30 JUN 2011 | DOI: 10.1002/cncr.26238

      Neoadjuvant gemcitabine and cisplatin chemotherapy was found to be capable of down-staging urothelial cancer in the bladder; however, no effect on disease in nodes was seen in this study.

    8. You have free access to this content
      Serum cell-free DNA in renal cell carcinoma : A diagnostic and prognostic marker (pages 82–90)

      Michela de Martino, Tobias Klatte, Andrea Haitel and Michael Marberger

      Article first published online: 28 JUN 2011 | DOI: 10.1002/cncr.26254

      The results from this study indicted that total serum cell-free DNA levels and CpG island methylation represent novel diagnostic serum biomarkers for patients with renal cell carcinoma. In addition, total serum cell-free DNA may be a useful prognostic biomarker that may assist in tailoring postoperative surveillance and therapy.

    9. Gynecologic Oncology
      You have free access to this content
      Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (pages 91–100)

      Lee E. Moore, Ruth M. Pfeiffer, Zhen Zhang, Karen H. Lu, Eric T. Fung and Robert C. Bast Jr.

      Article first published online: 29 JUN 2011 | DOI: 10.1002/cncr.26241

      In a study that investigated prediagnostically collected sera from a group of 118 women with invasive ovarian cancer and a control group of 951 healthy women who participated in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, analytical models that included cancer antigen 125 (CA 125) and 7 biomarkers failed to improve on the sensitivity of CA 125 alone. This was in contrast to observations in previous studies using postdiagnostically collected serum samples, in which improved sensitivity was observed with the addition of proteomic biomarkers to CA 125 alone.

    10. Head and Neck Disease
      You have free access to this content
      Early stage squamous cell cancer of the oral tongue—clinicopathologic features affecting outcome (pages 101–111)

      Ian Ganly, Snehal Patel and Jatin Shah

      Article first published online: 29 JUN 2011 | DOI: 10.1002/cncr.26229

      The presence of occult neck metastases was the main predictor of outcome in patients with early stage tongue cancer. The results from this study indicated that, with the exception of small superficial (<2 mm thick) T1 tumors, all patients should undergo elective neck dissection to stage the neck, and, if occult metastases are identified, then adjuvant postoperative radiation should be considered.

    11. Hematologic Malignancies
      You have free access to this content
      Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease (pages 112–117)

      Ferial Shihadeh, Valerie Reed, Stefan Faderl, L. Jeffrey Medeiros, Ali Mazloom, Mersiha Hadziahmetovic, Hagop Kantarjian, Pamela Allen, Leslie Ballas, Sherry Pierce and Bouthaina Dabaja

      Article first published online: 20 JUN 2011 | DOI: 10.1002/cncr.26253

      The objective of this study was to assess patients who had acute myeloid leukemia with and without central nervous system (CNS) disease to determine whether cytogenetic findings correlated with or predicted CNS involvement.

    12. You have free access to this content
      Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (pages 118–126)

      Franck E. Nicolini, Anna Turkina, Zhi-Xiang Shen, Neil Gallagher, Saengsuree Jootar, Bayard L. Powell, Carmino De Souza, Ming Zheng, Tomasz Szczudlo and Philipp le Coutre

      Article first published online: 5 JUL 2011 | DOI: 10.1002/cncr.26249

      ENACT is the largest clinical study of patients with chronic myeloid leukemia in the chronic phase (N = 1422) who failed prior imatinib therapy because of resistance or intolerance. This study confirms the clinical efficacy and safety of nilotinib for the treatment of these patients, which was observed in the phase 2 registration study.

    13. You have free access to this content
      Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome (pages 127–133)

      Iris Cordoba, José R. González-Porras, Benet Nomdedeu, Elisa Luño, Raquel de Paz, Esperanza Such, Mar Tormo, Teresa Vallespi, Rosa Collado, Blanca Xicoy, Rafael Andreu, Juan A. Muñoz, Francesc Solé, Jose Cervera, Consuelo del Cañizo and On behalf of the Spanish Myelodysplastic Syndrome Registry

      Article first published online: 29 JUN 2011 | DOI: 10.1002/cncr.26279

      Abnormalities involving chromosome 7 are frequent in myelodysplastic syndrome (MDS) and suggest a poor prognosis. In this study, the authors observed that isolated patients who had MDS with deletion of part of the long arm of chromosome (7q) had distinct clinicopathologic characteristics and better survival than patients who had MDS with isolated monosomy 7 (complete loss of chromosome 7). Therefore, the current results indicate that isolated 7q deletion no longer should be considered in the same prognostic category as monosomy 7.

    14. Hepatobiliary Disease
      You have free access to this content
      FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo (pages 134–146)

      Feng Fang, Lianyue Yang, Yiming Tao and Wei Qin

      Article first published online: 28 JUN 2011 | DOI: 10.1002/cncr.26251

      In this study, the authors originally investigated the expression levels, clinical relevance, and biologic function of the so-called factor that binds to inducer of short transcripts-1 (FBI-1) in patients with hepatocellular carcinoma (HCC). The findings revealed that FBI-1 was highly elevated in HCC tissues, and overexpression of FBI-1 was correlated with a poor prognosis in patients with HCC after hepatic resection; furthermore, FBI-1 was capable of promoting cell proliferation and enhancing chemotherapy resistance of HCC in vitro and in vivo, suggesting that FBI-1 may serve as a novel prognostic marker and therapeutic target for HCC.

    15. You have free access to this content
      Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma (pages 147–156)

      Julien Edeline, Eveline Boucher, Yan Rolland, Elodie Vauléon, Marc Pracht, Christophe Perrin, Catherine Le Roux and Jean-Luc Raoul

      Article first published online: 28 JUN 2011 | DOI: 10.1002/cncr.26255

      The results from this study provided data on the usefulness of assessing tumor vascularization in hepatocellular carcinoma with the use of modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. mRECIST characterized a population of 23% of responders who had a significantly better prognosis compared with nonresponding patients.

    16. Lung Disease
      You have free access to this content
      The prognostic impact of tumor cell expression of estrogen receptor-α, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer (pages 157–163)

      Dirk Rades, Cornelia Setter, Olav Dahl, Steven E. Schild and Frank Noack

      Article first published online: 28 JUN 2011 | DOI: 10.1002/cncr.26282

      Tumor cell expression of estrogen receptor-α, progesterone receptor (PR), and androgen receptor (AR) was evaluated in patients who received radiotherapy for stage II/III non-small cell lung cancer with respect to locoregional control, metastases-free survival, and overall survival. Expression of PR and AR was not found to be associated with outcomes.

    17. You have free access to this content
      Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy (pages 164–172)

      Suchita Pakkala, Zhengjia Chen, David Rimland, Taofeek K. Owonikoko, Clifford Gunthel, Johann R. Brandes, Nabil R. Saba, Dong M. Shin, Walter J. Curran Jr., Fadlo R. Khuri and Suresh S. Ramalingam

      Article first published online: 28 JUN 2011 | DOI: 10.1002/cncr.26242

      Lung cancer has emerged as the most common cause of death from non-acquired immunodeficiency syndrome-defining malignancies. For this report, the authors reviewed the outcome of patients with lung cancer at their institution who had human immunodeficiency virus (HIV) disease and noted a shorter latency from the diagnosis of HIV to lung cancer in women. A higher CD4 count was associated with improved lung cancer-related survival.

    18. Neuro-Oncology
      You have free access to this content
      The long-term postsurgical prognosis of patients with pineoblastoma (pages 173–179)

      Matthew Tate, Michael E. Sughrue, Martin J. Rutkowski, Ari J. Kane, Derick Aranda, LaShaun McClinton, LaShay McClinton, Igor J. Barani and Andrew T. Parsa

      Article first published online: 29 JUN 2011 | DOI: 10.1002/cncr.26300

      In this study, the authors comprehensively summarize the existing literature on pineoblastoma and identify variables and treatments that had an impact on patient outcomes. Patient age >5 years and gross total resection were associated with improved patient survival.

    19. Sarcoma
      You have free access to this content
      Reirradiation and hyperthermia for radiation-associated sarcoma (pages 180–187)

      Marianne A. A. de Jong, Sabine Oldenborg, S. Bing Oei, Vanessa Griesdoorn, M. Willemijn Kolff, Caro C. E. Koning and Geertjan van Tienhoven

      Article first published online: 28 JUN 2011 | DOI: 10.1002/cncr.26252

      Sixteen patients with radiation-associated sarcoma from the authors' institutions and 19 patients from the literature who received reirradiation with or without hyperthermia were analyzed. In contrast to the common assumption, the high response rate and the possibility of durable local control suggest that this treatment is promising.

    20. Discipline

      Bioethics and Legal Oncology
      You have free access to this content
      Conflict of interest in oncology publications : A survey of disclosure policies and statements (pages 188–195)

      Aaron S. Kesselheim, Joy L. Lee, Jerry Avorn, Amber Servi, William H. Shrank and Niteesh K. Choudhry

      Article first published online: 29 JUN 2011 | DOI: 10.1002/cncr.26237

      The authors found that disclosure policies and the definition of conflict of interest varied considerably among oncology journals. Many oncology journals did not publish disclosure statements, with deficiencies particularly among editorials and commentaries.

    21. Disparities Research
      You have free access to this content
      Do radiation use disparities influence survival in patients with advanced breast cancer? (pages 196–204)

      Steve R. Martinez, Warren H. Tseng, Robert J. Canter, Allen M. Chen, Steven L. Chen and Richard J. Bold

      Article first published online: 20 JUN 2011 | DOI: 10.1002/cncr.26231

      The current analysis shows that only black patients have poorer overall and disease-specific survival relative to whites, even when stratified by type of surgery and use of radiation. Therefore, this survival disparity is unlikely to be because of lack of radiation use.

    22. Epidemiology
      You have free access to this content
      Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer (pages 205–215)

      Jinliang Xing, Colin P. Dinney, Sanjay Shete, Maosheng Huang, Michelle A. Hildebrandt, Zhinan Chen and Jian Gu

      Article first published online: 20 JUN 2011 | DOI: 10.1002/cncr.26224

      In this large cancer association study, the authors identified several novel genetic predisposition variants in nucleotide excision repair pathway genes for bladder cancer and observed potential gene-gene and gene-environment interactions. The results reinforce the importance of a comprehensive, pathway-focused, and tagging single nucleotide polymorphism-based candidate gene approach to identify low-penetrance cancer-susceptibility loci.

    23. You have free access to this content
      Nativity and papillary thyroid cancer incidence rates among Hispanic women in California (pages 216–222)

      Pamela L. Horn-Ross, Ellen T. Chang, Christina A. Clarke, Theresa H. M. Keegan, Rudolph P. Rull, Thu Quach and Scarlett Lin Gomez

      Article first published online: 20 JUN 2011 | DOI: 10.1002/cncr.26223

      Incidence rates of papillary thyroid cancer vary by nativity and age among Hispanic women residing in California. These patterns can provide insight for future etiologic investigations of modifiable risk factors for this increasingly common and understudied cancer.

    24. You have free access to this content
      Associations of human leukocyte antigen class II genotypes with human papillomavirus 18 infection and cervical intraepithelial neoplasia risk (pages 223–231)

      Li-Chung Chuang, Chung-Yi Hu, Hui-Chi Chen, Pei-Jung Lin, Borheng Lee, Ching-Yu Lin, Mei-Hung Pan, San-Lin You, Chang-Yao Hsieh, Chien-Jen Chen and Community-Based Cancer Screening Program-Human Papillomavirus Study Group

      Article first published online: 20 JUN 2011 | DOI: 10.1002/cncr.26227

      Human leukocyte antigen alleles DRB1*0403 and DRB1*0405 are, respectively, associated with the high viral load and persistent infection of human papillomavirus type 18 (HPV18). The DRB1*0403 allele is associated with an increased risk of developing high-grade squamous intraepithelial lesions or cervical cancer after adjustment for viral load and persistent infection of HPV18.

    25. You have free access to this content
      An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma (pages 232–240)

      Junjie Feng, Seong-Tae Kim, Wennuan Liu, Jin Woo Kim, Zheng Zhang, Yi Zhu, Michael Berens, Jielin Sun and Jianfeng Xu

      Article first published online: 28 JUN 2011 | DOI: 10.1002/cncr.26250

      Representing one of the first attempts to systematically integrate various levels of alterations associated with the often complex cancer genomes and phenotypes, this study provided a holistic view and a mechanistic explanation over the functional connections of multiple 9p21.3-related events in glioblastoma multiforme, as well as clinically useful biomarker information for predicting the disease outcomes.

    26. Medical Oncology
      You have free access to this content
      Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer : Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial (pages 241–247)

      Antonio Llombart-Cussac, Amparo Ruiz, Antonio Antón, Agustí Barnadas, Silvia Antolín, José E. Alés-Martínez, Isabel Álvarez, Raquel Andrés, José A. García Saenz, Juan Lao, Eva Carrasco, Carmen Cámara, Isabel Casas and Miguel Martín

      Article first published online: 29 JUN 2011 | DOI: 10.1002/cncr.26299

      The authors designed an exploratory, open-label, randomized phase 2 study to investigate the activity and tolerability of exemestane and anastrozole as first-line hormone therapy and to explore the optimal aromatase inhibitor sequence in postmenopausal women with hormone-responsive, advanced breast cancer. A sequential strategy of anastrozole followed by exemestane appeared to be the more appropriate endocrine therapy option for these patients.

    27. Outcomes Research
      You have free access to this content
      Adjuvant therapy for elderly patients with resected gastric adenocarcinoma : Population-based practices and treatment effectiveness (pages 248–257)

      Karen E. Hoffman, Bridget A. Neville, Harvey J. Mamon, Lisa A. Kachnic, Matthew S. Katz, Craig C. Earle and Rinaa S. Punglia

      Article first published online: 20 JUN 2011 | DOI: 10.1002/cncr.26248

      In this population-based study, the authors did not detect a survival benefit from the administration of adjuvant chemoradiation therapy for resected gastric cancer in patients aged 65 years and older.

    28. You have free access to this content
      Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer : A decision analysis (pages 258–267)

      Ravi Parikh and David J. Sher

      Article first published online: 30 JUN 2011 | DOI: 10.1002/cncr.26272

      In this decision analysis of primary radiotherapy versus surgery for high-risk prostate cancer, primary radiotherapy was associated with a higher quality-adjusted life expectancy than surgery and adjuvant radiotherapy. However, a hypothetical trimodality paradigm of prostatectomy, adjuvant radiotherapy, and hormone therapy led to the highest quality-adjusted life expectancy, suggesting that a more aggressive treatment paradigm may benefit a meaningful population of men with high-risk disease.

    29. Pathology
      You have free access to this content
      Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation (pages 268–277)

      Jeannelyn S. Estrella, Asif Rashid, Jason B. Fleming, Matthew H. Katz, Jeffrey E. Lee, Robert A. Wolf, Gauri R. Varadhachary, Peter W. T. Pisters, Eddie K. Abdalla, Jean-Nicolas Vauthey, Hua Wang, Henry F. Gomez, Douglas B. Evans, James L. Abbruzzese and Huamin Wang

      Article first published online: 6 JUL 2011 | DOI: 10.1002/cncr.26243

      The authors demonstrated that post-therapy pathologic American Joint Committee on Cancer stage and the number of positive lymph nodes were independent prognostic factors for both disease-free and overall survival in a consecutive cohort of 240 patients with pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant chemoradiation followed by pancreaticoduodenectomy (PD). Pathologic evaluation of PD specimen and post-therapy pathologic tumor staging remained the key factors in predicting clinical outcome in patients with PDAC who received neoadjuvant chemoradiation and subsequent PD.

    30. Radiation Oncology
      You have free access to this content
      Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer : Interim analysis of a prospective randomized noninferiority trial (pages 278–287)

      Xiao Hu, Yong Bao, Li Zhang, Ying Guo, Yuan Yuan Chen, Kai Xin Li, Wei Hua Wang, Yuan Liu, Han He and Ming Chen

      Article first published online: 19 MAY 2011 | DOI: 10.1002/cncr.26119

      Preliminary results did not decrease local control of limited-stage small cell lung cancer. Mediastinal N3 disease was the only risk factor to predict outfield recurrence.

SEARCH

SEARCH BY CITATION